Experimental Study of the Vascular Prosthesis Manufactured by Electrospinning

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-31

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the Vascular prosthesis manufactured by Electrospinning is safe with respect to the development of thrombosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Suture-mediated Closure System Following Endovascular Peripheral Arterial Procedures

NCT05899478

Percutaneous Intervention Via Femoral Artery

COMPLETED NA

Efficacy and Safety Comparison of the Open and Endovascular Surgical Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Below the Knee, TASC D in Patients With Critical Limb Ischemia

NCT04583436

Atherosclerotic Ischemic Disease Critical Limb Ischemia Superficial Femoral Artery Occlusion +1 more

UNKNOWN NA

Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass.

NCT01113892

Peripheral Arterial Occlusive Disease

COMPLETED NA

Pilot Study to Asses the Function and Patency of Polyester-Coated Composite Bypasses From Autologous Varicose Veins

NCT00460291

Peripheral Arterial Disease Peripheral Bypass Surgery Bypass From Autologous Varicose Vein +1 more

UNKNOWN NA

The Clinical Application of Peripheral Embolization Coil Systems in Arteriovenous Embolization Within the Peripheral Vasculature

NCT07156409

Peripheral Arterial Hemorrhage Arteriovenous Malformation Arteriovenous Fistula +1 more

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To test the influence of the prostheses to hemostasis blood will be pumped through the vascular prosthesis or control silicone tube (both with identical inner diameter 1,7 mm) during 20 minutes at a linear velocity 10 cm/sec (corresponding to 18 ml/min). The tested prostheses (or control tubes) will be installed between two syringes with blood installed in the UTPS-1 instrument providing synchronical movement of pistons of both syringes. Installing UTPS-1 was designed and manufactured at the Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences consists of a mechanical pushers, equipped with clamps for syringes and pistons, stepper motor, electronic control unit and power supply.

UTPS-1 and polypropylene non-pyrogenic syringes filled with blood without any bulbs of air provides absence of contacts with air, pyrogens and minimize lysis of blood cells. UTPS-1 has no analogues, and does not require licensure, metrological control or obtaining of any other permits.

After pumping the blood will be separated into plasma and cell fraction according to standard laboratory methods. Primary blood (before any treatment), blood after pumping through silicon tube (control), and vascular prosthesis will be tested for hemostatic parameters.

Notification of basic and additional parameters being studied, which will be

evaluated in the study:

1. The initial parameters of blood hemostasis will be evaluated (Platelet count; Platelet aggregation; Prothrombin time, International Normalised Ratio \[INR\], activated partial thromboplastin time (aPTT), prothrombin Quick, thrombin time, soluble fibrin monomer complexes (SFMC), free hemoglobin and P- selectin concentrations).
2. To evaluate the influence of the prosthesis to circulating blood the same hemostasis characteristics wiil be evaluated in blood after 20 min of circulation through prosthesis and silicon tube (Platelet count; Platelet aggregation; Prothrombin time, International Normalised Ratio \[INR\], activated partial thromboplastin time (aPTT), prothrombin Quick, thrombin time, soluble fibrin monomer complexes (SFMC), the measurement of free hemoglobin, P- selectin).
3. Microscopy: a study of adhesion of blood cells on the surface of the prosthesis

Description of Design of the Research: this will be prospective (are marked in section Detailed Description)

Monocentred research

Defined indicators for each prosthesis

1\. hemostasis characteristics listed hereinabove for untreated blood (control)

2 hemostasis characteristics listed hereinabove in blood after 20 min circulation through silicone tube (control)

3 hemostasis characteristics listed hereinabove in blood after 20 min circulation through After the interaction with the experimental vascular prosthesis

Will be studied 4 types of vascular prostheses made by electrospinning

* polycaprolactone;
* polycaprolactone / gelatin/poorly permeable layer;
* polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer;
* nylon 6

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ARTERIAL OCCLUSIVE DISEASE

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Graft type - PCL

PCL - polycaprolactone

blood sampling procedure

Intervention Type PROCEDURE

30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary

Graft type - PCL/ gelatin

polycaprolactone/ gelatin/poorly permeable layer;

blood sampling procedure

Intervention Type PROCEDURE

30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary

Graft type - PLGA/PCL/gelatin

PLGA/PCL/gelatin - polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer

blood sampling procedure

Intervention Type PROCEDURE

30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary

Graft type - nylon 6

blood sampling procedure

Intervention Type PROCEDURE

30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sampling procedure

30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged from 18 to 50 years at the date of the informed consent signing;
* Patients without atherosclerosis
* Patients without blood pathology

Exclusion Criteria

* Patient did not sign the informed consent.
* Early postoperative period.
* Concomitant diseases such as atherosclerosis, blood pathology, venous thrombosis, malignancy, terminal cancer, infectious - inflammatory disease at the time of the study.
* Patients after implantation of a cardioverter-defibrillator; prior prosthetic heart valves or other implants, which can lead to mechanical damage to the blood cells.
* Receiving anticoagulants, antiplatelet, antibacterial drugs, NSAIDs.
* Myocardial infarction less than 3 months ago.
* Irreversible failure of major organs with an expected survival time of less than 1 year
* Pregnancy, lactation.
* Age above 50 years.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes